New patient treatment, phase 2 initiated

A patient was treated on Tuesday April 9th, 2019, in SpectraCure's clinical trial for the treatment of patients with recurrent prostate cancer, at University College London Hospital.

The treatment was performed with SpectraCure's photodynamic therapy (PDT) method. The procedure went as expected and the patient is doing well.

"It is gratifying that we are now officially entering the Phase 2 study together with our clinical partners," comments Masoud Khayyami, CEO.

The purpose of the Phase 2 study is to, with a larger statistical basis than in the Phase 1 study, show that the method is safe to use and that it has clinical effect.

For further information, please contact:
SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46 (0) 70 815 21 90

Certified Adviser is G&W Fondkommission, e-mail: ca@gwkapital.se, phone: +46(0) 8 503 000 50 

This information is information that SpectraCure AB is required to disclose under the EU Market Abuse Regulation. The information was provided, through the contact of the above contact person, for publication on April 10th, 2019 10:46 a.m.

Release

SpectraCure is developing the future systems for the treatment of internal solid cancer tumours. The goal of the proprietary and patented treatment system is to eliminate deep-seated cancer tumours and prolong the survival of cancer patients while maintaining their quality of life. When prostate cancer recurs, there are often no established treatment options other than lifelong hormone therapy, with its associated side effects. 

Facebook Linkedin Envelope